Health Care & Life Sciences » Pharmaceuticals | Sage Therapeutics Inc.

Sage Therapeutics Inc.

Sage Therapeutics Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
46.66 M
Public Float
32.67 M
Sage Therapeutics Inc.
Stock Exchange NASDAQ Stock Market
EPS
$9.74
Market Cap
$9.06 B
Shares Outstanding
51.15 M
Public Float
49.41 M

Profile

Address
215 First Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.sagerx.com
Updated 07/08/2019
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Financials

View All

Kevin Paul Starr
Chairman
Jeffrey M. Jonas
President, Chief Executive Officer & Director